MoonLake Immunotherapeutics: A Somewhat Complicated Story

(14min)

Summary

  • MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected.
  • SLK, a tri-specific IL-17A and IL-17F inhibiting nanobody, shows promise in treating HS and psoriatic arthritis (PsA), with Phase 3 trials underway.
  • Despite a crowded market, SLK's superior tissue penetration and favorable Phase 2b results position it as a potential best-in-class treatment.
  • An analysis around MoonLake Immunotherapies follows in the paragraphs below.
  • Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More »

Female studying DNA samples. Computer screens with DNA sequences

janiecbros

Shares of nanobody concern MoonLake Immunotherapeutics (NASDAQ:MLTX) have dipped a tad recently after rallying since June 2024 as any buyout premium fades as crucial data readout draws nearer. That said, output from its two pivotal trials in hidradenitis suppurativa, which will

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

51.12K Followers

Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.

Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of MLTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About MLTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MLTX

Related Stocks

SymbolLast Price% Chg
MLTX
--